| Item | Definition | Score | CDAA diet with/without antiplatelet agent | ||||
| CDAA | CDAA+ aspirin | CDAA+ ticlopidine | CDAA + cilostazol | CSAA | |||
| Steatosis | |||||||
| Grade | Parenchymal involvement | ||||||
| <5% | 0 | 0 | 0 | 0 | 0 | 6 | |
| 5–33% | 1 | 0 | 1 | 0 | 4 | 0 | |
| 33–66% | 2 | 1 | 3 | 3 | 2 | 0 | |
| >66% | 3 | 5 | 2 | 3 | 0 | 0 | |
| Average | 2.83 | 2.17* | 2.5 | 1.33** | 0 | ||
| Inflammation | |||||||
| Lobular inflammation | Assessment of all inflammatory foci | ||||||
| No foci | 0 | 0 | 1 | 0 | 2 | 4 | |
| <2 foci per 200× field | 1 | 3 | 4 | 4 | 4 | 2 | |
| 2–4 foci per 200× field | 2 | 2 | 1 | 2 | 0 | 0 | |
| >4 foci per 200× field | 3 | 1 | 0 | 0 | 0 | 0 | |
| Portal inflammation | Assessed under low magnification | ||||||
| None to minimal | 0 | 5 | 5 | 6 | 6 | 6 | |
| Greater than minimal | 1 | 1 | 1 | 0 | 0 | 0 | |
| Microgranulomas | Small aggregates of macrophages | ||||||
| Absent | 0 | 5 | 6 | 5 | 6 | 6 | |
| Present | 1 | 1 | 0 | 1 | 0 | 0 | |
| Large lipogranulomas | In portal areas or adjacent to central vein | ||||||
| Absent | 0 | 4 | 5 | 5 | 5 | 6 | |
| Present | 1 | 2 | 1 | 1 | 1 | 0 | |
| Average | 2.33 | 1.33* | 1.67 | 0.83** | 0.33 | ||
| Fibrosis | |||||||
| Stage | Method of Brunt | ||||||
| None | 0 | 0 | 0 | 0 | 0 | 6 | |
| Perivenular/perisinusoidal fibrosis | 1 | 0 | 3 | 2 | 5 | 0 | |
| Combined pericellular portal fibrosis | 2 | 4 | 3 | 4 | 1 | 0 | |
| Septal/bridging fibrosis | 3 | 2 | 0 | 0 | 0 | 0 | |
| Cirrhosis | 4 | 0 | 0 | 0 | 0 | 0 | |
| Average | 2.33 | 1.5* | 1.67* | 1.17** | 0 | ||
*p<0.05; **p<0.01.
CDAA, choline-deficient, l-amino acid-defined; CSAA, choline-sufficient, l-amino acid-defined; NAFL, non-alcoholic fattty liver disease; NASH, non-alcoholic steatohepatitis.